D. Watanabe

发表

Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L randomized clinical trial

H. Kaneto, A. Amano, A. Takami, 2020, Diabetes, obesity & metabolism.

Reduction of postprandial glucose by lixisenatide vs sitagliptin treatment in Japanese patients with type 2 diabetes on background insulin glargine: A randomized phase IV study (NEXTAGE Study)

Yuichiro Yamada, M. Senda, M. Tamura, 2017, Diabetes, obesity & metabolism.

Decreased cognitive function is associated with preceding severe hypoglycemia and impaired blood glucose control in the elderly individuals with type 1 diabetes

Hiroyuki Sano, J. Terasaki, A. Imagawa, 2022, Diabetology International.

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Y. Terauchi, Y. Iwamoto, H. Watada, 2014, Cardiovascular Diabetology.

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials

Y. Terauchi, Y. Iwamoto, H. Watada, 2014, Expert opinion on pharmacotherapy.

iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post‐hoc analysis of the LixiLan JP‐L trial

H. Kaneto, K. Iizuka, D. Yabe, 2021, Journal of diabetes investigation.

Benefits of the fixed‐ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time‐to‐control analysis of the LixiLan JP phase 3 trials

H. Kaneto, Y. Terauchi, H. Watada, 2020, Diabetes, obesity & metabolism.

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP‐O2 trial

K. Iizuka, D. Yabe, M. Baxter, 2021, Diabetes, obesity & metabolism.

Decreased cognitive function is associated with preceding severe hypoglycemia and impaired blood glucose control in the elderly individuals with type 1 diabetes

Hiroyuki Sano, J. Terasaki, A. Imagawa, 2022, Diabetology International.

Perioperative infusion of dexmedetomidine at a high dose reduces postoperative analgesic requirements: a randomized control trial

D. Watanabe, E. Masaki, M. Kitamura, 2011, Journal of Anesthesia.

Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study

D. Yabe, Y. Seino, N. Inagaki, 2015, Hormone and Metabolic Research.

Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study

Y. Terauchi, Y. Seino, D. Watanabe, 2017, Journal of diabetes investigation.

O R I G I N a L I N V E S T I G a T I O N Open Access

Y. Terauchi, Y. Iwamoto, H. Watada, 2022 .